UCB (UCBJY) Ending Cash Position : $1,647 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is UCB Ending Cash Position?

UCB's Ending Cash Position for the quarter that ended in Dec. 2024 was $1,647 Mil.

UCB's quarterly Ending Cash Position declined from Dec. 2023 ($939 Mil) to Jun. 2024 ($461 Mil) but then increased from Jun. 2024 ($461 Mil) to Dec. 2024 ($1,647 Mil).

UCB's annual Ending Cash Position increased from Dec. 2022 ($910 Mil) to Dec. 2023 ($939 Mil) and increased from Dec. 2023 ($939 Mil) to Dec. 2024 ($1,647 Mil).

UCB Ending Cash Position Historical Data

The historical data trend for UCB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Ending Cash Position Chart

UCB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

1,585.16

1,405.65

909.96

938.93

1,647.12

UCB Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															909.96	494.04	938.93	460.71	1,647.12

UCB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

UCB's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	901.57	+	745.55
	=	1,647

UCB's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	448.168	+	1198.952
	=	1,647

UCB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of UCB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJY) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).